Biotech Day In Review: Novartis International AG Pulls Zelnorm Off The Market

Published: Apr 02, 2007

Centient Biotech Investor submits: Novartis (NVS) suspended sales of Zelnorm, a treatment for irritable bowel syndrome with constipation, at the request of the FDA. The agency noticed a statistically significant number of cases of angina pectoris in patients taking the drug.

>>> Discuss This Story

Back to news